Company: OSRH
Filing Date: 2025-06-23
Form Type: 424B3
Source: 0001213900-25-056351
Chunk: 109

Company: OSR Holdings, Inc.
Filing Date: 2025-06-23
Form: 424B3
Chunk 109
---
Dr. Joong Myung Cho became
a Director of the Company upon the Closing of the Business Combination. Dr. Cho has been Chairman and CEO of CG Pharmaceuticals,
Inc. since October 2008 and previously served as Chairman and CEO of Hwail Pharmaceuticals Co. Ltd. from August 2013 to December 2022.
Dr. Cho is the founder of Crystal Genomics and the former Chairman & President (July 2000 to March 2023). He
has over 40 years of experience in biopharmaceutical industry covering from discovery of novel pharmaceuticals through R&D and
commercialization. Dr. Cho has previously served as the executive Senior Vice President and Director of R&D Biotech Research
Institute at LG Life Science (formerly LG Chem.) from 1984 to 2000. During his tenure, biopharmaceutical R&D at LG became the leading
life science company in Korea where it grew from just a few research scientists to several hundred prior to his departure. He has successfully
introduced 10 different recombinant products such as growth hormones of human, bovine, and porcine, hepatitis B vaccine, interferon alpha
and gamma, GM-CSF, EPO, etc. Moreover, four drug candidates were licensed out to multinational pharmaceutical companies under his supervision
and one of them is approved by FDA (US). On the basis of such achievements, Dr. Cho has received many awards and acted as a member
of governmental committees. He received his Ph.D. from University of Houston and worked as a post-doc in Baylor College of Medicine.
Dr. Cho is an author of more than 80 publications in books and journals including Nature, and an inventor of more than 200 patents
filed. Dr. Cho is well qualified to serve as a Director because of long-standing career experiences both as a biotech entrepreneur
and the R&D Head of a major life sciences company in Korea (LG Group).

Family Relationships

There are no family
relationships among our directors and executive officers.

Number and Terms of Office of Officers and Directors

We have seven directors and five officers. In
accordance with Nasdaq corporate governance requirements, we are not required to hold an annual meeting until one year after our first
fiscal year end following our listing on Nasdaq. The term of office of our initial directors will expire at our first annual meeting
of stockholders.

Our officers are appointed by the board of directors
and serve at the discretion of the board of directors,